GeneTex, Inc.

Established in 1997 by a group of renowned scientists, GeneTex`s corporate mission remains clear. While commercial polyclonal and monoclonal antibodies have driven progress in science and medicine since their introduction, the generation of reliable antibodies remains an essential goal in the quest for data accuracy and reproducibility. On the forefront of high-quality antibody manufacturing, GeneTex has now successfully incorporated recombinant monoclonal antibody technology into its product development platform. This technology has numerous well-documented advantages, with consistency of performance being of paramount significance. GeneTex`s capability in this area enhances its position in the research community and the biotechnology industry and spearheads its efforts to provide the most trusted antibody products available.